Skip to main content

Parkinson's Disease

Parkinson disease (PD) and related atypical parkinsonism syndromes (most importantly multiple system atrophy — MSA) are a high-volume but generally non-reconstructive NLUTD population. Symptoms are dominantly storage-phase OAB with preserved coordination, and management is largely pharmacologic and behavioral. The reconstructive urologist's role is mostly diagnostic (distinguishing PD from MSA, from coexisting BPH) and risk-avoidance (anticholinergics in a cognitively vulnerable population, functional incontinence in a mobility-impaired population).

See Neurogenic Lower Urinary Tract Dysfunction for the general framework. For the procedural therapies referenced below, see Intradetrusor OnabotulinumtoxinA, Sacral Neuromodulation, and Percutaneous Tibial Nerve Stimulation; for refractory MSA, the Ileal Conduit is the salvage option.

Epidemiology​

  • US prevalence of PD >1 million; incidence rises with age.
  • ~25–40% of PD patients have clinically relevant urinary symptoms.[2]
  • OAB / DO is the dominant phenotype.
  • Urinary symptoms correlate with motor severity and autonomic dysfunction.
  • MSA is much rarer but has a far more aggressive autonomic phenotype — urinary symptoms often precede the motor diagnosis and are severe from onset.

Pathophysiology​

  • PD is a suprapontine disease. Loss of basal ganglia dopaminergic input disinhibits the pontine micturition center, producing detrusor overactivity usually with preserved coordination (true DSD is atypical and merits reassessment). Storage pressures are typically low — upper-tract risk is rare.
  • MSA has both suprapontine and sacral involvement. Patients develop early and severe OAB with later retention, DSD-like patterns, and profound sphincter denervation. Urinary retention with elevated PVR is common and an important clue.
  • Coexisting BPH — most PD patients are older men, so mixed PD-OAB + BPH outlet obstruction is common.

Evaluation​

Initial:

  • History — symptom onset vs motor symptom onset (early = MSA red flag), fall risk, medications, cognition, caregiver status.
  • UA, PVR, voiding diary.

Adjunctive (as indicated):

  • Urodynamics — recommended before prostate surgery in men with PD to distinguish outlet obstruction from PD OAB (changes postoperative expectations), and whenever MSA is suspected.
  • Renal US + eGFR in patients with elevated PVR or MSA phenotype.

PD vs MSA — the urologic clue​

FeaturePDMSA
Onset of urinary symptomsLate, follows motorEarly — often before motor
OABYesYes, often severe
PVRUsually lowElevated — early retention
Orthostatic hypotensionModestSevere
Response to dopaminergic therapyGood (motor)Poor
EMG of external anal sphincterNormalDenervation pattern

Early urinary retention + severe orthostatic hypotension + poor dopamine response should raise concern for MSA and change counseling about prognosis and procedure selection.

Management​

Behavioral and pharmacologic first line​

  • Timed voiding, bowel program, fluid management.
  • Pelvic-floor PT — modest benefit in selected patients.
  • β3-adrenergic agonists (mirabegron, vibegron) — often attractive when avoiding anticholinergic burden. AUA permits either class or combination; it does not require a beta-3-first sequence for all PD patients. Disease-specific evidence is stronger for mirabegron than for assuming a class-wide effect.[3][1]
  • Antimuscarinics — individualize benefit versus cognition, constipation, retention and total anticholinergic burden; lower CNS penetration does not establish absence of cognitive risk. Avoid oxybutynin IR in cognitively impaired patients.
  • Desmopressin — selective use for nocturia; monitor sodium, avoid in frail / older patients with fall risk.

Intradetrusor onabotulinumtoxinA​

  • Effective for refractory PD OAB.
  • Caution: post-injection urinary retention may tip a borderline patient into full retention requiring CIC — many PD patients lack the dexterity for CIC. Discuss explicitly before proceeding.

Prostate / outlet surgery in men with PD​

  • TURP, HoLEP, simple prostatectomy etc. are appropriate when obstruction is documented on urodynamics.
  • Counsel about persistent OAB symptoms post-op — outlet surgery does not fix the neurogenic component.
  • In MSA, outlet surgery is generally contraindicated — worsens incontinence in a patient with already failing sphincter function.

Catheter-based management​

  • Indwelling urethral catheter — sometimes the pragmatic choice in late PD / MSA with severe mobility limitation and caregiver support.
  • CIC — feasible in early PD with intact dexterity; becomes harder as tremor progresses.
  • Suprapubic catheter — preferred over urethral in men for long-term drainage.

Sacral neuromodulation and PTNS​

  • SNM is a reasonable option in PD with refractory OAB.[1]
  • MRI compatibility — PD patients often have co-indications for brain imaging (e.g., if DBS surgery is planned); verify device MRI-conditional status.
  • DBS interaction — for PD patients with deep-brain stimulators, coordinate with the movement-disorders team.
  • Usually not used in MSA because of the aggressive autonomic phenotype.

Reconstructive surgery​

  • Rare in PD. Augmentation is almost never indicated because upper-tract risk is low.
  • MSA — occasionally needs urinary diversion for refractory combined retention and incontinence, but advanced care planning and prognosis often drive the decision.

Common Scenarios​

PD with OAB and mixed BPH​

Pragmatic pathway: (1) β3 agonist + α-blocker; (2) urodynamics if equivocal; (3) outlet surgery for documented obstruction with residual OAB treatment; (4) botulinum only after CIC capacity confirmed.

PD with nocturia​

Very common and multifactorial — fluid intake, peripheral edema redistribution, sleep fragmentation, depression. Treat the modifiable factors first (elevation, compression, evening fluid restriction) before adding desmopressin.

PD with dementia / functional incontinence​

Shifts emphasis to caregiver-directed toileting schedules, incontinence products, and careful medication review (anticholinergic burden, diuretics). Avoid aggressive pharmacologic management that risks cognitive / fall side effects.

MSA with retention​

Teach CIC early while dexterity remains; plan for SPC as progression limits function.

Clinical Correlations for the Reconstructive Urologist​

  • Differentiate PD from MSA. Early urinary retention with severe orthostasis + anal-sphincter EMG denervation = think MSA. This matters for prognosis and for avoiding futile outlet surgery.
  • Choose storage medication individually. Avoid unnecessary anticholinergic burden in cognitively vulnerable patients; no universal sequence applies.
  • Urodynamics before outlet surgery in men with PD. OAB + BPH mix is common; operating without documenting obstruction leaves an unhappy patient.
  • CIC is often impractical in late PD. Plan drainage around that reality (SPC rather than ongoing CIC failure).
  • Functional incontinence is often bigger than neurogenic incontinence in late PD. Caregiver strategies, toilet transfer aids, clothing modifications, and scheduled voiding matter more than drugs.
  • MRI-compatibility and DBS coexistence drive implant selection.

See Also​

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

2. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

3. Sakakibara R, Panicker J, Finazzi-Agro E, et al.; ICS Parkinson Disease Subcommittee. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35:551–563. doi:10.1002/nau.22764.